Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Stem Cells Infusion in Advanced Heart Failure
NCT02871466Phase 4Unknown
- Sponsor
- University of Campania Luigi Vanvitelli
- Start
- Jan 2010
- Primary completion
- Jan 2022
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Autologous Mesenchymal Stem Cells in heart failure (HF), sponsored by University of Campania Luigi Vanvitelli. Primary endpoints: NYHA class improvement at 12 months, Reduction in hospitalization rate at 12 months and 1 more. Status: unknown.
02
Drugs
Autologous Mesenchymal Stem Cells
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT02871466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02871466.